TRCT
NMRA icon

Tower Research Capital (TRC)’s Neumora Therapeutics NMRA Stock Holding History

Tower Research Capital (TRC)’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.93K Sell
4,068
-13,651
-77% -$35.4K ﹤0.01% 3995
2025
Q4 		$31.7K Sell
17,719
-3,262
-16% -$7.14K ﹤0.01% 2770
2025
Q3 		$38.2K Sell
20,981
-2,246
-10% -$3.63K ﹤0.01% 2737
2025
Q2 		$17K Buy
23,227
+3,316
+17% +$2.51K ﹤0.01% 3764
2025
Q1 		$19.9K Buy
19,911
+18,593
+1,411% +$31.8K ﹤0.01% 2978
2024
Q4 		$14K Sell
1,318
-3,624
-73% -$43.4K ﹤0.01% 3489
2024
Q3 		$65.3K Buy
4,942
+1,256
+34% +$14.7K ﹤0.01% 2566
2024
Q2 		$36.2K Buy
3,686
+1,050
+40% +$10.9K ﹤0.01% 3348
2024
Q1 		$36.2K Buy
2,636
+78
+3% +$1.26K ﹤0.01% 2493
2023
Q4 		$43.6K Buy
+2,558
New +$31.4K ﹤0.01% 3220

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

Tower Research Capital (TRC)'s NMRA Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Neumora Therapeutics (NMRA) stake by 77% in Q1 2026, selling an estimated $35.4K and leaving 4,068 shares worth $7.93K. The position accounts for ﹤0.01% of the portfolio, ranked #3995.

Tower Research Capital (TRC) first reported a position in NMRA in Q4 2023 and has held it in 10 quarters since. The position peaked at $65.3K in Q3 2024. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • Tower Research Capital (TRC) held 4,068 shares of Neumora Therapeutics worth $7.93K as of Q1 2026.
  • Tower Research Capital (TRC) sold 13,651 Neumora Therapeutics shares in Q1 2026, an estimated $35.4K.
  • Neumora Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3995 holding.
  • Tower Research Capital (TRC) first reported a position in Neumora Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Tower Research Capital (TRC)'s Neumora Therapeutics position peaked at $65.3K in Q3 2024.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.